Bio-Techne Corp (FRA:TE1)
€ 76.5 1 (1.32%) Market Cap: 11.96 Bil Enterprise Value: 12.28 Bil PE Ratio: 65.48 PB Ratio: 6.45 GF Score: 92/100

Bio-Techne Corp at Stephens Investment Conference (Virtual) Transcript

Dec 02, 2021 / 10:00PM GMT
Release Date Price: €101.5 (-1.93%)
Jacob K. Johnson
Stephens Inc., Research Division - Analyst

I'm Jacob Johnson, the life science tools and diagnostics analyst here at Stephens. Really pleased to have the team from Bio-Techne here with us in Nashville today, including CEO Chuck Kummeth and Dave Clair from Investor Relations and Corp Dev.

Chuck, I'll turn it over to you for any opening comments you want to make, and then we'll go into Q&A.

Charles R. Kummeth
Bio-Techne Corporation - CEO, President & Director

Sure. Glad to be here. It's my first time ever in Nashville, and I wish we were located here. But Bio-Techne, where I've been here almost 9 years, it's a 40-some year old company at this point. Everyone knows R&D Systems. We, the team and I, have done a fairly good job of acquisitions and building it out over the years, but we're now -- we're still a tools company primarily, but we're expanding into diagnostics areas as well as other areas and higher forms of instrumentation.

We've got a big -- I think a big head start on cell and gene therapy workflow. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot